Neupogen 30 MU Solution for Injection 0.3mg/ml Malta - English - Medicines Authority

neupogen 30 mu solution for injection 0.3mg/ml

amgen europe b.v. minervum 7061, 4817 zk breda, netherlands - filgrastim - solution for injection - filgrastim 0.3 mg/ml - immunostimulants

Neupogen Singleject 30 MU Solution for Injection (0.6mg/ml) Malta - English - Medicines Authority

neupogen singleject 30 mu solution for injection (0.6mg/ml)

amgen europe b.v. minervum 7061, 4817 zk breda, netherlands - filgrastim - solution for injection - filgrastim 0.6 mg/ml - immunostimulants

Neupogen Singleject 48 MU Solution for Injection (0.96 mg/ml) Malta - English - Medicines Authority

neupogen singleject 48 mu solution for injection (0.96 mg/ml)

amgen europe b.v. minervum 7061, 4817 zk breda, netherlands - filgrastim - solution for injection - filgrastim 0.96 mg/ml - immunostimulants

Neupogen 48 MU Solution for Injection (0.3 mg/ml) Malta - English - Medicines Authority

neupogen 48 mu solution for injection (0.3 mg/ml)

amgen europe b.v. minervum 7061, 4817 zk breda, netherlands - filgrastim - solution for injection - filgrastim 0.3 mg/ml - immunostimulants

Parareg European Union - English - EMA (European Medicines Agency)

parareg

dompé biotec s.p.a. - cinacalcet - hypercalcemia; parathyroid neoplasms; hyperparathyroidism - calcium homeostasis - treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy.mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate (see section 5.1).reduction of hypercalcaemia in patients with:-parathyroid carcinoma.- primary hpt for whom parathyroidectomy would be indicated on the basis of serum calciumlevels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Vectibix European Union - English - EMA (European Medicines Agency)

vectibix

amgen europe b.v. - panitumumab - colorectal neoplasms - antineoplastic agents - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri., in second-line in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)., as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

XGEVA Israel - English - Ministry of Health

xgeva

amgen europe b.v. - denosumab - solution for injection - denosumab 120 mg / 1.7 ml - denosumab - denosumab - prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma and in adults with bone metastases from solid tumours.treatment of adult and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

RevitaCAM European Union - English - EMA (European Medicines Agency)

revitacam

zoetis belgium sa - meloxicam - oxicams - dogs - alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders in dogs.

Nespo European Union - English - EMA (European Medicines Agency)

nespo

dompé biotec s.p.a. - darbepoetin alfa - kidney failure, chronic; anemia; cancer - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients.treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Ristempa European Union - English - EMA (European Medicines Agency)

ristempa

amgen europe b.v. - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)